Janux ends development of Tumor Activated T Cell Engager asset
Source: SeekingAlpha
2026-04-27 16:36:52 ET
More on Janux Therapeutics
- Janux Therapeutics GAAP EPS of -$0.51 beats by $0.16
- Seeking Alpha’s Quant Rating on Janux Therapeutics
- Historical earnings data for Janux Therapeutics
- Financial information for Janux Therapeutics
Read the full article on Seeking Alpha
For further details see:
Janux ends development of Tumor Activated T Cell Engager asset
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
2.41% G/L:
$14.42 Last:
367,172 Volume:
$14.12 Open:
JANX Latest News
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
